The juvenile gangliosidoses: A timeline of clinical change

Kelly E. King; Sarah Kim; Chester B. Whitley; Jeanine R. Jarnes-Utz

doi:10.1016/j.ymgmr.2020.100676

The juvenile gangliosidoses: A timeline of clinical change

Kelly E. King, Sarah Kim, Chester B. Whitley, Jeanine R. Jarnes-Utz

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Background: The gangliosidoses are rare inherited diseases that result in pathologic accumulation of gangliosides in the central nervous system and other tissues, leading to severe and progressive neurological impairment and early death in the childhood forms. No treatments are currently approved for the gangliosidoses, and development of treatments is impaired by limited understanding of the natural history of these diseases. Objective: The objective of this study is to improve understanding of the juvenile gangliosidoses phenotypes and the late-infantile phenotypic subtype. Methods: Through a prospective natural history study of subjects with juvenile GM1- and GM2-gangliosidosis, a timeline of clinical changes was developed for the classic juvenile phenotypes and the late-infantile phenotypes and results of serial neurodevelopmental testing was analyzed. Results: Several candidate ‘outcome measures’ were identified: changes in ambulation and verbalization skills, the communication domain from neurodevelopmental testing and the caregiver-reported socialization domain. Conclusions: The most common symptoms leading caregivers to seek a genetic diagnosis were changes in ambulation and verbalization.

Original language	English (US)
Article number	100676
Journal	Molecular Genetics and Metabolism Reports
Volume	25
DOIs	https://doi.org/10.1016/j.ymgmr.2020.100676
State	Published - Dec 2020

Bibliographical note

Funding Information:
This work was supported by the National Institutes of Health through the Lysosomal Disease Network ( U54NS065768 ). The Lysosomal Disease Network ( U54NS065768 ) is a part of the National Institutes of Health (NIH) Rare Diseases Clinical Research Network (RDCRN), supported through collaboration between the NIH Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Science (NCATS), the National Institute of Neurological Disorders and Stroke (NINDS), and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

Funding Information:
The authors thank the children and their parents and caregivers for participation as the subjects of this long term longitudinal natural history study. This work was supported by the National Institutes of Health through the Lysosomal Disease Network ( U54NS065768 ). The Lysosomal Disease Network ( U54NS065768 ) is a part of the National Institutes of Health (NIH) Rare Diseases Clinical Research Network (RDCRN) , supported through collaboration between the NIH Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Science (NCATS), the National Institute of Neurological Disorders and Stroke (NINDS), and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Assistance with statistical analyses, graphics, and formatting of the final manuscript was provided by Julie Harriague, pH.D., (4Clinics, Paris, France funded by Lysogene, Paris, France).

Publisher Copyright:
© 2020 The Authors

Keywords

Adolescent
Child
Disease progression
GM1-gangliosidosis
Inherited metabolic diseases
Tay-Sachs disease

Publisher link

10.1016/j.ymgmr.2020.100676

Find It

Find It at U of M Libraries

Cite this

@article{bd1c8f43d44f4dd28dbfd4d449444b22,

title = "The juvenile gangliosidoses: A timeline of clinical change",

abstract = "Background: The gangliosidoses are rare inherited diseases that result in pathologic accumulation of gangliosides in the central nervous system and other tissues, leading to severe and progressive neurological impairment and early death in the childhood forms. No treatments are currently approved for the gangliosidoses, and development of treatments is impaired by limited understanding of the natural history of these diseases. Objective: The objective of this study is to improve understanding of the juvenile gangliosidoses phenotypes and the late-infantile phenotypic subtype. Methods: Through a prospective natural history study of subjects with juvenile GM1- and GM2-gangliosidosis, a timeline of clinical changes was developed for the classic juvenile phenotypes and the late-infantile phenotypes and results of serial neurodevelopmental testing was analyzed. Results: Several candidate {\textquoteleft}outcome measures{\textquoteright} were identified: changes in ambulation and verbalization skills, the communication domain from neurodevelopmental testing and the caregiver-reported socialization domain. Conclusions: The most common symptoms leading caregivers to seek a genetic diagnosis were changes in ambulation and verbalization.",

keywords = "Adolescent, Child, Disease progression, GM1-gangliosidosis, Inherited metabolic diseases, Tay-Sachs disease",

author = "King, {Kelly E.} and Sarah Kim and Whitley, {Chester B.} and Jarnes-Utz, {Jeanine R.}",

note = "Funding Information: This work was supported by the National Institutes of Health through the Lysosomal Disease Network ( U54NS065768 ). The Lysosomal Disease Network ( U54NS065768 ) is a part of the National Institutes of Health (NIH) Rare Diseases Clinical Research Network (RDCRN), supported through collaboration between the NIH Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Science (NCATS), the National Institute of Neurological Disorders and Stroke (NINDS), and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Funding Information: The authors thank the children and their parents and caregivers for participation as the subjects of this long term longitudinal natural history study. This work was supported by the National Institutes of Health through the Lysosomal Disease Network ( U54NS065768 ). The Lysosomal Disease Network ( U54NS065768 ) is a part of the National Institutes of Health (NIH) Rare Diseases Clinical Research Network (RDCRN) , supported through collaboration between the NIH Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Science (NCATS), the National Institute of Neurological Disorders and Stroke (NINDS), and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Assistance with statistical analyses, graphics, and formatting of the final manuscript was provided by Julie Harriague, pH.D., (4Clinics, Paris, France funded by Lysogene, Paris, France). Publisher Copyright: {\textcopyright} 2020 The Authors",

year = "2020",

month = dec,

doi = "10.1016/j.ymgmr.2020.100676",

language = "English (US)",

volume = "25",

journal = "Molecular Genetics and Metabolism Reports",

issn = "2214-4269",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - The juvenile gangliosidoses

T2 - A timeline of clinical change

AU - King, Kelly E.

AU - Kim, Sarah

AU - Whitley, Chester B.

AU - Jarnes-Utz, Jeanine R.

N1 - Funding Information: This work was supported by the National Institutes of Health through the Lysosomal Disease Network ( U54NS065768 ). The Lysosomal Disease Network ( U54NS065768 ) is a part of the National Institutes of Health (NIH) Rare Diseases Clinical Research Network (RDCRN), supported through collaboration between the NIH Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Science (NCATS), the National Institute of Neurological Disorders and Stroke (NINDS), and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Funding Information: The authors thank the children and their parents and caregivers for participation as the subjects of this long term longitudinal natural history study. This work was supported by the National Institutes of Health through the Lysosomal Disease Network ( U54NS065768 ). The Lysosomal Disease Network ( U54NS065768 ) is a part of the National Institutes of Health (NIH) Rare Diseases Clinical Research Network (RDCRN) , supported through collaboration between the NIH Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Science (NCATS), the National Institute of Neurological Disorders and Stroke (NINDS), and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Assistance with statistical analyses, graphics, and formatting of the final manuscript was provided by Julie Harriague, pH.D., (4Clinics, Paris, France funded by Lysogene, Paris, France). Publisher Copyright: © 2020 The Authors

PY - 2020/12

Y1 - 2020/12

N2 - Background: The gangliosidoses are rare inherited diseases that result in pathologic accumulation of gangliosides in the central nervous system and other tissues, leading to severe and progressive neurological impairment and early death in the childhood forms. No treatments are currently approved for the gangliosidoses, and development of treatments is impaired by limited understanding of the natural history of these diseases. Objective: The objective of this study is to improve understanding of the juvenile gangliosidoses phenotypes and the late-infantile phenotypic subtype. Methods: Through a prospective natural history study of subjects with juvenile GM1- and GM2-gangliosidosis, a timeline of clinical changes was developed for the classic juvenile phenotypes and the late-infantile phenotypes and results of serial neurodevelopmental testing was analyzed. Results: Several candidate ‘outcome measures’ were identified: changes in ambulation and verbalization skills, the communication domain from neurodevelopmental testing and the caregiver-reported socialization domain. Conclusions: The most common symptoms leading caregivers to seek a genetic diagnosis were changes in ambulation and verbalization.

AB - Background: The gangliosidoses are rare inherited diseases that result in pathologic accumulation of gangliosides in the central nervous system and other tissues, leading to severe and progressive neurological impairment and early death in the childhood forms. No treatments are currently approved for the gangliosidoses, and development of treatments is impaired by limited understanding of the natural history of these diseases. Objective: The objective of this study is to improve understanding of the juvenile gangliosidoses phenotypes and the late-infantile phenotypic subtype. Methods: Through a prospective natural history study of subjects with juvenile GM1- and GM2-gangliosidosis, a timeline of clinical changes was developed for the classic juvenile phenotypes and the late-infantile phenotypes and results of serial neurodevelopmental testing was analyzed. Results: Several candidate ‘outcome measures’ were identified: changes in ambulation and verbalization skills, the communication domain from neurodevelopmental testing and the caregiver-reported socialization domain. Conclusions: The most common symptoms leading caregivers to seek a genetic diagnosis were changes in ambulation and verbalization.

KW - Adolescent

KW - Child

KW - Disease progression

KW - GM1-gangliosidosis

KW - Inherited metabolic diseases

KW - Tay-Sachs disease

UR - http://www.scopus.com/inward/record.url?scp=85096176055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85096176055&partnerID=8YFLogxK

U2 - 10.1016/j.ymgmr.2020.100676

DO - 10.1016/j.ymgmr.2020.100676

M3 - Article

C2 - 33240792

AN - SCOPUS:85096176055

SN - 2214-4269

VL - 25

JO - Molecular Genetics and Metabolism Reports

JF - Molecular Genetics and Metabolism Reports

M1 - 100676

ER -

The juvenile gangliosidoses: A timeline of clinical change

Abstract

Bibliographical note

Keywords

Publisher link

Find It

Other files and links

Fingerprint

Cite this